APG-1252

APG-1252 · Ascentage Pharma Group Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for APG-1252, covering 2024-01-23 to 2025-10-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients [Phase 1]